{
    "brief_title": "Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment",
    "phase": "Phase 2",
    "drugs": "['olaparib, durvalumab, tremelimumab']",
    "drugs_list": [
        "olaparib",
        "durvalumab",
        "tremelimumab"
    ],
    "diseases": "['Immunotherapy']",
    "diseases_list": [
        "Immunotherapy"
    ],
    "enrollment": "270.0",
    "inclusion_criteria": "inclusion criteria: \n\n inclusion criteria from STEP 1: \n\n Capable of giving signed informed consent \n\n Exome sequencing of tumor and constitutive DNA should have been already performed \n\n Patients must be diagnosed with a solid malignancy with the following cancer histologically confirmed with specified inclusion for each cohort: \n\n Metastatic breast cancer: \n\n \u2022 In second line \n\n \u2022 third line and after \n\n Metastatic lung cancer: \n\n Non-small cell lung cancer \n\n Must have progressed after at least a first line with platinum based therapy \n\n Metastatic head and Neck cancer \n\n \u2022 Must have progressed after at least a first line with platinum based therapy \n\n Metastatic endometrial cancer \u2022 Progression after 1 prior systemic, platinum-based chemotherapy regimen for EC. Participants may have received up to 1 additional line of platinum-based chemotherapy if given in the neoadjuvant or adjuvant treatment setting. There is no restriction regarding prior hormonal therapy \n\n Metastatic clear cell renal cancer \n\n \u2022 Must have progressed after at least a line with anti-angiogenic agent. Metastatic pancreatic cancer \n\n \u2022 Must have progressed after at least a line with FOLFIRINOX regimen and/or Gemcitabin based chemotherapy \n\n Locally advanced or metastatic ovarian cancer \n\n \u2022 Must have received at least one and no more than two lines of prior platinum-containing therapy and progressed after the most recent platinum therapy in a platinum-sensitive timeframe (more than 6 months from the last dose of platinum before randomization) \n\n Metastatic urothelial cancer \u2022 From the second line and regardless previous treatment (except immunotherapy) \n\n Metastatic prostate cancer \n\n Documented evidence of metastatic castration resistant prostate cancer (mCRPC) \n\n Ongoing therapy with LHRH analog or bilateral orchiectomy \n\n Must have progressed on prior new hormonal agent (enzalutamine or abiraterone) and taxane chemotherapy \n\n Presence of mutation in homologous repair gene \n\n Age >18 years \n\n Performance status ECOG of 0 or 1. \n\n Life expectancy \u2265 6 months. \n\n At least one lesion measurable as defined by standard imaging criteria for the patient's tumor type (RECIST v1.1) \n\n Body weight >30 kg. \n\n 10. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment \n\n Postmenopausal or evidence of non-childbearing status for women of childbearing potential \n\n Male patients must use a condom during treatment of STEP1 (olaparib) and STEP2 (durvalumab and tremelimumab) and for 180 days after the last dose when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential \n\n Patient is willing and able to comply with the protocol for the duration of the study. \n\n For all oral medications patients must be able to comfortably swallow capsules; \n\n inclusion criteria STEP 2 \n\n 16. CT Scan evaluation after 6 weeks of olaparib should present response or stable disease as defined by RECIST v1.1 criteria. \n\n ",
    "exclusion_criteria": ": \n\n ",
    "brief_summary": "The study propose to generate a clinical trial based on precision medicine to evaluate the use of immunotherapy in patients with altered homologous recombination repair genes and without progression after prior targeted therapy.",
    "NCT_ID": "NCT04169841"
}